The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in unprecedented crisis to the global health. The SARS-CoV-2 has spread into over 188 countries and sickened over 10M people worldwide. A timely response to virus outbreaks in terms of the developments of both diagnostic tools and therapeutics is essential to combat such invisible enemies. To support these studies, Sino Biological has developed a comprehensive panel of antibodies and antigens for SARS-CoV-2. Sino Biological also specializes in recombinant antigen and antibody production. The ProVirTM collection is the world largest viral antigen bank, including over 800 proteins from 350 viral strains.
Up to 15th, June, there are 116 publications that have cited SARS-CoV-2 reagents or services providing by Sino Biological Inc.
1. Renhong Yan,et al.Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2.Science.2020
2. Lamers, MM,et al.SARS-CoV-2 productively infects human gut enterocytes.Science.2020
3. Rockx, B,et al.Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.Science.2020
4. Yu, J,et al.DNA vaccine protection against SARS-CoV-2 in rhesus macaques.Science.2020
5. Xiangyang Chi,et al.A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.Science.2020
6. Bin Ju,et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection.Nature.2020
7. Linlin Bao,et al.The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice.Nature.2020
8. Dora Pinto,et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature.2020
9. Bojkova, D,et al.Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.Nature.2020
10. "Yunlong Cao,et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.cell.2020"
11. Cao, Y,et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.Cell.2020
12. Wrapp, Daniel,et al.Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.Cell.2020
13. Sun, J,et al.Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.Cell.2020
14. Wang, H,et al.Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.Cell.2020
15. Wang, C,et al.A human monoclonal antibody blocking SARS-CoV-2 infection.Nature Communications .2020
16. Ou, X,et al.Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.Nature Communications .2020
17. Deng, W,et al.Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques.Nature Communications .2020
18. Smith, TRF,et al.Immunogenicity of a DNA vaccine candidate for COVID-19.Nature Communications .2020
19. Ni, L,et al.Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.Immunity.2020
20. Long, QX,et al.Antibody responses to SARS-CoV-2 in patients with COVID-19.Nature Medicine.2020
21. "Amanat F,et al.A serological assay to detect SARS-CoV-2 seroconversion in humans.Nature Medicine.2020"
22. Wu, Y,et al.Identification of Human Single-Domain Antibodies against SARS-CoV-2.Cell Host Microbe.2020
23. Zhang, H,et al.Activation of Peroxiredoxin 1 by Fluvastatin Effectively Protects from Inflammation and SARS-CoV-2.Cell Metabolism.2020
24. Huibin LvCross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.Cell Reports.2020
25. Yi, C,et al.Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.Cell. Mol. Immunol..2020
26. Xiao, F,et al.Evidence for gastrointestinal infection of SARS-CoV-2.Gastroenterology.2020
27. Seo, G,et al.Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.ACS Nano.2020
28. Su, H,et al.Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.Kidney Int..2020
29. Ye, L,et al.Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.Cellular & Molecular Immunology.2020
30. Bing ZhaoRecapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids.Protein&Cell.2020
31. Chia, WN,et al.Serological differentiation between COVID-19 and SARS infections.Emerg Microbes Infect.2020
32. Sun B,et al.Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.Emerg Microbes Infect..2020
33. Shan-Meng Lin,et al.Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.J. Med. Chem..2020
34. Liu, X,et al.Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction.Acta Pharm Sin B.2020
35. Liu, X,et al.Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.Acta Pharm Sin B.2020
36. Okba, NMA,et al.Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.Emerging Infect. Dis..2020
37. Sangeun Jeon,et al.Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.Antimicrob Agents Chemother.2020
38. Zeng, W,et al.Biochemical characterization of SARS-CoV-2 nucleocapsid protein.Biochemical and Biophysical Research Communications.2020
39. Fujita, R,et al.Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system.Biochemical and Biophysical Research Communications.2020
40. Chen, Z,et al.A DNA Aptamer Based Method for Detection of SARS-CoV-2 Nucleocapsid Protein.Virol Sin.2020
41. Huang, S,et al.Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.Biomedical Journal.2020
42. Musarrat, F,et al.The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARSCoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.J Med Virol.2020
43. Pu, T,et al.Evaluate Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity by Pseudoviral Particles.J. Med. Virol..2020
44. Carnevale, S,et al.Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of CoViD-19 patient with diarrhea.J. Med. Virol..2020
45. Prasad, ASV;Local Immunity Concept in the Context of the Novel Corona Viral Infection: A Consideration.bioRxiv.2020
46. Zeng, X,et al.Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.Antibody Therapeutics.2020
47. Khan, S,et al.Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.BioRxiv.2020
48. Thornburg, N,et al.Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient.bioRxiv.2020
49. Chunyun Sun,et al.SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development.bioRxiv.2020
50. Milewska, A,et al.HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV.bioRxiv.2020
51. Wang, C,et al.Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2.bioRxiv.2020
52. Li, Y,et al.Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1.bioRxiv.2020
53. Xiong, H,et al.Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells.bioRxiv.2020
54. Zhang, Q,et al.SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation.bioRxiv.2020
55. Zhang, Y,et al.Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry.bioRxiv.2020
56. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020
57. Tan, X,et al.Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples.bioRxiv.2020
58. Zhu, Y,et al.Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.bioRxiv.2020
59. Walter, JD,et al.Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain.BioRxiv.2020
60. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray.BioRxiv.2020
61. Chi X,et al.Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain.bioRxiv.2020
62. Kim, SY,et al.Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry.bioRxiv.2020
63. Si L,et al.Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics.bioRxiv.2020
64. Liu L,et al.SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent manner.bioRxiv.2020
65. Zha L,et al.Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles.bioRxiv.2020
66. Romano, M,et al.An engineered stable mini-protein to plug SARS-Cov2 Spikes.bioRxiv.2020
67. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020
68. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray.BioRxiv.2020
69. Hedde, PN,et al.A Modular Microarray Imaging System for Highly Specific COVID-19 Antibody Testing.bioRxiv.2020
70. Ghazizadeh, Z,et al.Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men.bioRxiv.2020
71. Finch, CL,et al.Characteristic and quantifiable COVID-19-like abnormalities in CT-and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis).bioRxiv.2020
72. Cai, Y,et al.Distinct conformational states of SARS-CoV-2 spike protein.bioRxiv.2020
73. Zang, J,et al.Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.bioRxiv.2020
74. Zost, SJ,et al.Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.bioRxiv.2020
75. Zhang, Y,et al.The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I.bioRxiv.2020
76. Corbett, K,et al.SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.bioRxiv.2020
77. Yang, Y,et al.The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.bioRxiv.2020
78. Daly, J,et al.Neuropilin-1 is a host factor for SARS-CoV-2 infection.bioRxiv.2020
79. Liu, D,et al.Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection.bioRxiv.2020
80. Mesci, P,et al.Sofosbuvir protects human brain organoids against SARS-CoV-2.bioRxiv.2020
81. Bosco-Lauth, A,et al.Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats.bioRxiv.2020
82. Yao, D,et al.Human H-ferritin presenting RBM of spike glycoprotein as potential vaccine of SARS-CoV-2.bioRxiv.2020
83. Liu, L,et al.A translatable subunit nanovaccine for COVID-19.ChemRxiv.2020
84. Song, Y,et al.Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.ChemRxiv.2020
85. Sobrevilla, JMV;¿ Por qué los pacientes con diabetes o hipertensión son más susceptibles a tener COVID-19?.Conference.2020
86. Harcourt, Jennifer,et al.Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States.Emerging Infectious Diseases.2020
87. Feng, Siqin,et al.Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases.2020
88. Zeng, X,et al.Molecular Detection of SARS-CoV-2 in Formalin Fixed Paraffin Embedded Specimens.JCI Insight.2020
89. Larsen, CP,et al.Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19).Kidney Int Rep.2020
90. Jiang, H,et al.Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray.medRxiv.2020
91. Bo Diao,et al.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv.2020
92. Linlin Bao,et al.Reinfection could not occur in SARS-CoV-2 infected rhesus macaques.medRxiv.2020
93. Linlin Bao,et al.Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route.medRxiv.2020
94. Ke Wang,et al.SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.medRxiv.2020
95. Feng, Z,et al.The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes.medRxiv.2020
96. Wei, C,et al.Cholesterol Metabolism--Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies.medRxiv.2020
97. McAndrews, KM,et al.Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19.medRxiv.2020
98. Norman, M,et al.Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients.medRxiv.2020
99. Randad, PR,et al.COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva.medRxiv.2020
100. Rosenberg, ES,et al.Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York.medRxiv.2020
101. Phipps, WS,et al.SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity.medRxiv.2020
102. Chakraborty, S,et al.Symptomatic SARS-CoV-2 infections display specific IgG Fc structures.medRxiv.2020
103. Rosendal, E,et al.Detection of asymptomatic SARS-CoV-2 exposed individuals by a sensitive S-based ELISA..medRxiv.2020
104. Mittal, A,et al.COVID-19 Pandemic: Insights into Structure, Function, and hACE2 Receptor Recognition by the SARS-CoV-2.preprints.2020
105. Simon, D,et al.Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection.Research Square.2020
106. Kanjanasirirat, P,et al.High-Content Screening of Thai Medicinal Plants Reveals Boesenbergia rotunda Extract and its Component Panduratin A as Anti-SARS-CoV-2 Agents.Research Square.2020
107. Yang, J,et al.Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.Research Square.2020
108. Bdr-Eldeen, O;What we should understand about SARS-COV-2 GENOME..researchgate.net.2020
109. Ravichandran, Supriya,et al.Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.Science Translational Medicine.2020
110. Zhou, R,et al.Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.SSRN Journal.2020
111. Cheng, Y,et al.Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.SSRN Journal.2020
112. 彭浩然,et al.上海 2 株严重急性呼吸综合征冠状病毒 2 的分离与鉴定.第二军医大学学报.2020
113. Yu, P,et al.Age-related rhesus macaque models of COVID-19.Anim Models Exp Med.2020
114. Turista, D,et al.Distribution of COVID-19 and Phylogenetic Tree Construction of SARS-CoV-2 in Indonesia.J. Pure Appl. Microbiol..2020
115. Belete, T;A review on Promising vaccine development progress for COVID-19 disease.Vacunas.2020
116. Gan, JH;Discovery of small molecule therapeutics for the Middle Eastern respiratory syndrome-coronavirus (MERS-CoV).Thesis.2020
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
Here we list part products cited in those publications.
| Cat# | Molecule | Description | Total Cites | Citation Number |
| 40591-V08H | Spike S1 | SARS-CoV-2 Spike S1,His tag, HPLC-verified | 20 | 7，17，18，22，27，29，32，47，49，51，55，57，60，68，92，93，96，98，109，113 |
| 40589-V08B1 | Spike S1+S2 ECD | SARS-CoV-2 Spike S1+S2 ECD, His tag | 13 | 11，18，47，55，59，60，61，64，68，84，96，99，109 |
| 40592-V05H | Spike RBD | SARS-CoV-2 Spike RBD, mFc tag, HPLC-verified | 13 | 1，8，12，29，47，53，59，60，61，68，73，74，84 |
| 40588-V08B | NP-CoV | SARS-CoV-2 Nucleocapsid,His tag | 6 | 32，47，60，68，99，101 |
| 40590-V08B | Spike S2 | SARS-CoV-2 Spike S2,His tag | 6 | 24，47，58，60，68，109 |
| 40592-V08B | Spike RBD | SARS-CoV-2 Spike RBD,His tag | 6 | 11，22，29，46，61，84 |
| 40591-V02H | Spike S1 | SARS-CoV-2 Spike S1,Fc tag | 5 | 47，56，60，67，68 |
| 40592-V08H | Spike RBD | SARS-CoV-2 Spike RBD,His tag | 4 | 66，97，99，109 |
| 40591-V05H1 | Spike S1 | SARS-CoV-2 Spike S1,mFc Tag | 3 | 47，60，68 |
| 40592-V02H | Spike RBD | SARS-CoV-2 Spike RBD,Fc tag | 1 | 70 |
| 40592-V08B-B | Spike RBD | SARS-CoV-2 Spike RBD,His tag | 1 | 11 |
| 40592-V31H | Spike RBD | SARS-CoV-2 Spike RBD,rFc Tag | 1 | 8 |
| 40150-V08B1 | Spike S1 | SARS-CoV Spike S1,His tag | 9 | 8，18，20，47，49，58，60，61，68 |
| 40143-V08B | NP-CoV | SARS-CoV Nucleocapsid,His tag | 5 | 20，36，47，60，68 |
| 40150-V08B2 | Spike RBD | SARS-CoV Spike RBD,His tag | 4 | 47，58，60，68 |
| 40150-V31B2 | Spike RBD | SARS-CoV Spike RBD,rFc Tag | 4 | 47，49，60，68 |
| 40524-V08E | PLpro | SARS-CoV PLpro,His tag | 3 | 47，60，68 |
| 40069-V08H | Spike S1 | MERS-CoV Spike S1,His tag | 5 | 27，47，49，60，68 |
| 40068-V08B | NP-CoV | MERS-CoV Nucleocapsid,His tag | 3 | 47，60，68 |
| 40069-V08B | Spike S1+S2 ECD | MERS-CoV Spike S1+S2 ECD,His tag | 3 | 47，60，68 |
| 40069-V08B1 | Spike S1 | MERS-CoV Spike S1,His tag | 3 | 47，60，68 |
| 40070-V08B | Spike S2 | MERS-CoV Spike S2,His tag | 3 | 47，60，68 |
| 40071-V05B | Spike RBD | MERS-CoV Spike RBD,mFc Tag | 3 | 47，60，68 |
| 40071-V08B1 | Spike RBD | MERS-CoV Spike RBD,His tag | 3 | 47，60，68 |
| 40071-V31B | Spike RBD | MERS-CoV Spike RBD,rFc Tag | 3 | 47，60，68 |
| 40071-V31B1 | Spike RBD | MERS-CoV Spike RBD,rFc Tag | 3 | 47，60，68 |
| 40603-V08H | HE-CoV | HCoV-OC43 HE-CoV,His tag | 3 | 47，60，68 |
| 40607-V08B | Spike S1+S2 ECD | HCoV-OC43 Spike S1+S2 ECD,His tag | 3 | 47，60，68 |
| 40600-V08H | Spike S1 | HCoV-NL63 Spike S1,His tag | 4 | 21，47，60，68 |
| 40604-V08B | Spike S1+S2 ECD | HCoV-NL63 Spike S1+S2 ECD,His tag | 3 | 47，60，68 |
| 40021-V08H | Spike S1 | HCoV-HKU1 Spike S1,His tag | 3 | 47，60，68 |
| 40602-V08H | Spike S1 | HCoV-HKU1 Spike S1,His tag | 3 | 47，60，68 |
| 40606-V08B | Spike S1+S2 ECD | HCoV-HKU1 Spike S1+S2 ECD,His tag | 3 | 47，60，68 |
| 40601-V08H | Spike S1 | HCoV-229E Spike S1,His tag | 4 | 21，47，60，68 |
| 40605-V08B | Spike S1+S2 ECD | HCoV-229E Spike S1+S2 ECD,His tag | 4 | 47，60，68，99 |
| 11049-V08B | RSV-F | RSV RSV-F,His tag | 3 | 47，60，68 |
| 11070-V08H | RSV-G | RSV RSV-G,His tag | 3 | 47，60，68 |
| 13029-V08H | RSV-G | RSV RSV-G,His tag | 3 | 47，60，68 |
| 40037-V08B | RSV-F | RSV RSV-F,His tag | 3 | 47，60，68 |
| 11716-V08H | HA1 | Influenza B HA1,His tag | 3 | 47，60，68 |
| 11716-V08H1 | HA1 | Influenza B HA1,His tag | 3 | 47，60，68 |
| 40498-V08B | HA | Influenza B HA,His tag | 3 | 47，60，68 |
| 40498-V08H1 | HA | Influenza B HA,His tag | 3 | 47，60，68 |
| 10108-H08H | ACE2 | Human ACE2,His tag, HPLC-verified | 3 | 29，61，84 |
| 10108-H02H | ACE2 | Human ACE2,Fc tag | 1 | 51 |
| 10108-H05H | ACE2 | Human ACE2,Fc tag | 1 | 46 |
| 10108-H08B | ACE2 | Human ACE2,His tag, HPLC-verified | 1 | 11 |
| 10602-HNAE | TNF | Human TNF,native | 1 | 22 |
| 40103-V08H | HA1 | H7N9 HA1,His tag | 3 | 47，60，68 |
| 40103-V08H1 | HA1 | H7N9 HA1,His tag | 3 | 47，60，68 |
| 10003-V06H1 | HA1 | H5N1 HA1,His & Fc Tag | 3 | 47，60，68 |
| 10003-V06H3 | HA1 | H5N1 HA1,His & Fc Tag | 3 | 47，60，68 |
| 40354-V08B | HA1 | H3N2 HA1,His tag | 3 | 47，60，68 |
| 40354-V08H1 | HA1 | H3N2 HA1,His tag | 3 | 47，60，68 |
| 40035-V08H | HA1 | H1N1 HA1,His tag | 3 | 47，60，68 |
| 40035-V08H1 | HA1 | H1N1 HA1,His tag | 3 | 47，60，68 |
| 40458-V08B | DcCoV-NP | DcCoV Nucleocapsid,His tag | 3 | 47，60，68 |
| Cat# | Description | Antigen | Type | Total Cites | Citation Number |
| 40143-T62 | SARS-CoV Nucleocapsid Antibody | NP-CoV | Rabbit PAb | 4 | 3，26，28，35 |
| 40150-T52 | SARS-CoV Spike Antibody | Spike | Rabbit PAb | 4 | 43，48，49，86 |
| 40143-R019 | SARS-CoV-2 Nucleocapsid Antibody | NP-CoV | Rabbit MAb | 3 | 9，89，95 |
| 40150-R007 | SARS-CoV-2 Spike Antibody | Spike | Rabbit MAb | 3 | 27，51，94 |
| 40150-T62 | SARS-CoV Spike S1 Antibody | Spike S1 | Rabbit PAb | 3 | 16，88，104 |
| 40592-T62 | SARS-CoV-2 Spike RBD Antibody | Spike RBD | Rabbit PAb | 3 | 47，60，68 |
| 10108-RP01 | Human ACE2 Antibody | ACE2 | Rabbit PAb | 2 | 30，95 |
| 40143-R001 | SARS-CoV Nucleocapsid Antibody | NP-CoV | Rabbit MAb | 2 | 37，91 |
| 10108-T56 | Human ACE2 Antibody | ACE2 | Rabbit PAb | 1 | 26 |
| 11695-RP01 | HIV Gag-p24 Antibody | Gag-p24 | Rabbit PAb | 1 | 16 |
| 11973-MM05T-H | M13 Antibody | M13 | Mouse MAb | 1 | 46 |
| 40068-MM10 | MERS-CoV Nucleocapsid Antibody | NP-CoV | Mouse MAb | 1 | 50 |
| 40068-RP02 | MERS-CoV Nucleocapsid Antibody | NP-CoV | Rabbit PAb | 1 | 33 |
| 40070-MM11 | MERS-CoV Spike s2 Antibody | Spike s2 | Mouse MAb | 1 | 16 |
| 40150-D001 | SARS-CoV Spike Antibody | Spike | Chimeric MAb | 1 | 63 |
| 40150-MM02 | SARS-CoV Spike S1 Antibody | Spike S1 | Mouse MAb | 1 | 16 |
| 40150-RP01 | SARS-CoV Spike S1 Antibody | Spike S1 | Rabbit PAb | 1 | 49 |
| HG1K | Human IgG1, kappa Isotype Control | kappa Isotype Control | 1 | 11 | |
| SSA009 | Goat Anti-Human IgG Secondary Antibody (Biotin) | Secondary Antibody | 1 | 19 |
| Product Type | Cat# | Description | Total Cites | Citation Number |
| ELISA | KIT40591 | SARS-CoV-2 (2019-nCoV) Spike ELISA Kit | 1 | 11 |
| Gene | VG40150-G-N | Human SARS coronavirus (SARS-CoV) Spike glycoprotein Gene ORF cDNA clone expression plasmid (Codon Optimized) | 1 | 49 |
| Gene | VG40589-UT | SARS-CoV-2 (2019-nCoV) Spike Gene ORF cDNA clone expression plasmid (Codon Optimized) | 1 | 49 |
| Gene | VG40592-CH | SARS-CoV-2 (2019-nCoV) Spike RBD Gene ORF cDNA clone expression plasmid, C-His tag (Codon Optimized) | 1 | 97 |
| Gene | CV022 | pCMV3-SP-N-Myc Negative Control Vector (N-terminal Myc-tagged) | 1 | 42 |
| Gene | HG10108-UT | Human ACE2 / Angiotensin-Converting Enzyme 2 Gene ORF cDNA clone expression plasmid | 1 | 49 |
| Transfection Reagent | STF02 | Sinofection Transfection Reagent | 2 | 49，65 |
| IP Kit | BA10600 | Immunoprecipitation Kit -Immunomagnetic Beads Protein A | 1 | 84 |
| Cell Culture Medium | M293TII | SMM 293-TII Expression Medium (Serum free, with Glutamine, complete medium) | 1 | 52 |
